GSK vs. UHS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at GSK and UHS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
GSK trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, UHS is a standard domestic listing.
| Symbol | GSK | UHS |
|---|---|---|
| Company Name | GSK plc | Universal Health Services, Inc. |
| Country | United Kingdom | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Health Care Providers & Services |
| Market Capitalization | 79.91 billion USD | 11.56 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | March 28, 1980 | July 9, 1981 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of GSK and UHS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | GSK | UHS |
|---|---|---|
| 5-Day Price Return | -2.21% | -1.25% |
| 13-Week Price Return | 0.24% | -4.96% |
| 26-Week Price Return | 2.13% | -3.93% |
| 52-Week Price Return | -11.92% | -23.33% |
| Month-to-Date Return | 2.93% | 9.09% |
| Year-to-Date Return | 8.39% | 1.20% |
| 10-Day Avg. Volume | 4.83M | 0.75M |
| 3-Month Avg. Volume | 6.50M | 0.88M |
| 3-Month Volatility | 24.72% | 30.39% |
| Beta | 0.96 | 1.30 |
Profitability
Return on Equity (TTM)
GSK
24.18%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
In the upper quartile for the Pharmaceuticals industry, GSK’s Return on Equity of 24.18% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
UHS
18.62%
Health Care Providers & Services Industry
- Max
- 26.03%
- Q3
- 13.74%
- Median
- 8.26%
- Q1
- 4.13%
- Min
- -3.62%
In the upper quartile for the Health Care Providers & Services industry, UHS’s Return on Equity of 18.62% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
GSK
10.82%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
GSK’s Net Profit Margin of 10.82% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.
UHS
7.66%
Health Care Providers & Services Industry
- Max
- 12.40%
- Q3
- 5.93%
- Median
- 1.96%
- Q1
- 0.93%
- Min
- -6.10%
A Net Profit Margin of 7.66% places UHS in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
GSK
16.22%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
GSK’s Operating Profit Margin of 16.22% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
UHS
10.99%
Health Care Providers & Services Industry
- Max
- 19.05%
- Q3
- 10.21%
- Median
- 4.22%
- Q1
- 1.98%
- Min
- -4.27%
An Operating Profit Margin of 10.99% places UHS in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | GSK | UHS |
|---|---|---|
| Return on Equity (TTM) | 24.18% | 18.62% |
| Return on Assets (TTM) | 5.77% | 8.60% |
| Net Profit Margin (TTM) | 10.82% | 7.66% |
| Operating Profit Margin (TTM) | 16.22% | 10.99% |
| Gross Profit Margin (TTM) | 71.77% | -- |
Financial Strength
Current Ratio (MRQ)
GSK
0.87
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
GSK’s Current Ratio of 0.87 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
UHS
1.29
Health Care Providers & Services Industry
- Max
- 2.01
- Q3
- 1.49
- Median
- 1.30
- Q1
- 0.94
- Min
- 0.17
UHS’s Current Ratio of 1.29 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
GSK
1.17
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
GSK’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 1.17. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
UHS
0.65
Health Care Providers & Services Industry
- Max
- 2.17
- Q3
- 1.18
- Median
- 0.74
- Q1
- 0.45
- Min
- 0.00
UHS’s Debt-to-Equity Ratio of 0.65 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
GSK
2.37
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
In the lower quartile for the Pharmaceuticals industry, GSK’s Interest Coverage Ratio of 2.37 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
UHS
9.05
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.15
- Median
- 5.45
- Q1
- 2.04
- Min
- -4.44
UHS’s Interest Coverage Ratio of 9.05 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | GSK | UHS |
|---|---|---|
| Current Ratio (MRQ) | 0.87 | 1.29 |
| Quick Ratio (MRQ) | 0.57 | 1.19 |
| Debt-to-Equity Ratio (MRQ) | 1.17 | 0.65 |
| Interest Coverage Ratio (TTM) | 2.37 | 9.05 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
GSK
4.26%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
With a Dividend Yield of 4.26%, GSK offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
UHS
0.45%
Health Care Providers & Services Industry
- Max
- 5.38%
- Q3
- 2.22%
- Median
- 0.55%
- Q1
- 0.00%
- Min
- 0.00%
UHS’s Dividend Yield of 0.45% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
GSK
54.01%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
GSK’s Dividend Payout Ratio of 54.01% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
UHS
4.19%
Health Care Providers & Services Industry
- Max
- 186.69%
- Q3
- 74.82%
- Median
- 26.76%
- Q1
- 0.00%
- Min
- 0.00%
UHS’s Dividend Payout Ratio of 4.19% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | GSK | UHS |
|---|---|---|
| Dividend Yield (TTM) | 4.26% | 0.45% |
| Dividend Payout Ratio (TTM) | 54.01% | 4.19% |
Valuation
Price-to-Earnings Ratio (TTM)
GSK
17.09
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
GSK’s P/E Ratio of 17.09 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
UHS
9.33
Health Care Providers & Services Industry
- Max
- 55.89
- Q3
- 30.85
- Median
- 21.17
- Q1
- 12.63
- Min
- 0.00
In the lower quartile for the Health Care Providers & Services industry, UHS’s P/E Ratio of 9.33 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
GSK
1.85
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
GSK’s P/S Ratio of 1.85 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
UHS
0.71
Health Care Providers & Services Industry
- Max
- 3.10
- Q3
- 1.74
- Median
- 0.67
- Q1
- 0.24
- Min
- 0.00
UHS’s P/S Ratio of 0.71 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
GSK
3.84
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
GSK’s P/B Ratio of 3.84 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
UHS
1.66
Health Care Providers & Services Industry
- Max
- 7.61
- Q3
- 4.32
- Median
- 2.53
- Q1
- 1.14
- Min
- 0.77
UHS’s P/B Ratio of 1.66 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | GSK | UHS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 17.09 | 9.33 |
| Price-to-Sales Ratio (TTM) | 1.85 | 0.71 |
| Price-to-Book Ratio (MRQ) | 3.84 | 1.66 |
| Price-to-Free Cash Flow Ratio (TTM) | 12.54 | 13.05 |